ENTITY
Telix Pharmaceuticals

Telix Pharmaceuticals (TLX AU)

50
Analysis
Health CareAustralia
Telix Pharmaceuticals Limited operates as a biotechnology company. The Company develops and commercializes molecularly-targeted radiation therapy for the treatment of prostate, renal, and brain cancer. Telix Pharmaceuticals serves patients worldwide.
more
02 Jul 2020 20:42Issuer-paid

Telix Pharmaceuticals - Major developments coming up

We expect 2020 to be a major turning point for Telix Pharmaceuticals. The regulatory submissions for illumet will determine whether the company...

Share
07 May 2020 14:46Issuer-paid

Telix Pharmaceuticals - Making progress despite headwinds

The NDA submission for illumet has been delayed slightly by COVID-19 but is expected to be submitted in Q220 (from March-April guidance). A...

Share
28 Feb 2020 16:34Issuer-paid

Telix Pharmaceuticals - Progress on clinical, regulatory and BD fronts

Telix has had a raft of announcements, marking its steady progress in a range of areas. Notably, the company received feedback from the FDA...

Share
20 Aug 2018 16:18Issuer-paid

Telix Pharmaceuticals - Targeted radiation to image and treat cancer

Telix has assembled a portfolio of promising molecularly targeted radiation (MTR) therapeutic and imaging products for three different cancers....

Share
13 Dec 2017 17:44

Aussie Healthcare Daily: 12 & 13 Dec 2017

The Aussie Healthcare Daily is a summary of major news and announcements from ASX-listed healthcare companies as well as developments and trends in...

Logo
416 Views
Share
x